Skip to content
Screener

Shattuck Labs, Inc. STTK Financing Cash Flow

Financing Cash Flow at other companies

Eli Lilly logo
Eli LillyLLY
$8.43B+777%
Johnson & Johnson logo
Johnson & JohnsonJNJ
-$8.78B-54.9%
Amgen logo
AmgenAMGN
-$1.48B+44.6%
AbbVie logo
AbbVieABBV
$919M+173%
Aclaris Therapeutics logo
Aclaris TherapeuticsACRS
$91K+1,111%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$410.21M+87,565%

Other financials

Income statement

See full
Revenue-
Operating income-$16.2M-24.0%
Net income-$15.2M-21.6%
EPS (diluted)-$0.12+50.0%

Balance sheet

See full
Cash & equivalents$63.3M+25.4%
Total debt$2.7M-10.0%
Total equity$211.1M+270%
Total assets$220.7M+243%

Cash flow

See full
Operating cash flow-$10.2M+2.4%
CapEx$78.0K
Free cash flow-$10.3M+1.6%

Valuation

See full
Market cap$681.93M+1,826%
Enterprise value$621.3M-5,241%
P/S681.9×+670×

Profitability

See full
Operating margin-5,578.7%-15,316pp
Net margin-5,256.8%-14,625pp
FCF margin-4,124%-23,818pp

Returns & leverage

See full
Return on equity-39.2%-12.5pp
Debt / equity0.0×
Current ratio27.6×+17.3×

Where this comes from

Reported directly by Shattuck Labs, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: Shattuck Labs, Inc.’s 10-Q, filed August 11, 2026.

Filed
Aug 11, 2026, 6:57 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-055483
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Proceeds from the exercise of common stock warrants52,778
Proceeds from the exercises of stock options and purchases pursuant to employee stock purchase plan3168
Taxes paid related to net share settlement of equity awards(269)(65)
Net cash provided by (used in) financing activities153,814(57)
Net increase (decrease) in cash and cash equivalents9,107(6,920)
Cash and cash equivalents, beginning of period54,19257,387
Cash and cash equivalents, end of period$63,299$50,467
Supplemental disclosures of non-cash financial activities:

Item 1. Condensed Financial Statements (Unaudited)

FAQ

What is Shattuck Labs, Inc.'s financing cash flow?
Shattuck Labs, Inc. (STTK) reported financing cash flow of $128.01M in Q2 2026.
What is the long-term trend for Shattuck Labs, Inc.'s financing cash flow?
Over 4 years (2021 to 2025), Shattuck Labs, Inc.'s financing cash flow has grown at a 119.2% compound annual growth rate (CAGR), from $1.93M to $44.57M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about Shattuck Labs, Inc.'s financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude